Accepted statements related to SARS-CoV-2 vaccination for patients with IBD by the IOIBD
| Accepted statements | Proportion agreement | Strength of agreement (Mean) | SD |
| Efficacy and safety of the various SARS-CoV-2 vaccines for patients with IBD | |||
| SARS-CoV-2 vaccination will be effective in patients with IBD to prevent COVID-19. | 82.8% | 8.13 | 1.46 |
| Patients with IBD should receive the same vaccine dosing regimen as patients without IBD. | 85.9% | 8.44 | 1.62 |
| Patients with IBD receiving SARS-CoV-2 vaccination should be referred to registries tracking vaccination effects. | 95.3% | 9.05 | 1.25 |
| Messenger RNA vaccines are safe to administer to patients with IBD. | 82.5% | 7.92 | 1.74 |
| Replication-incompetent vector vaccines are safe to administer to patients with IBD. | 95.2% | 8.81 | 1.02 |
| Inactivated SARS-CoV-2 vaccines are safe to administer to patients with IBD. | 89.1% | 8.16 | 1.78 |
| Recombinant SARS-CoV-2 vaccines are safe to administer to patients with IBD. | 90.2% | 8.18 | 1.61 |
| SARS-CoV-2 vaccines that contain whole or fragments of coronavirus proteins combined with an adjuvant to enhance immune response are safe to administer to patients with IBD. | 76.6% | 7.55 | 1.89 |
| Live attenuated vaccines for SARS-CoV-2 are not considered safe for patients with IBD who are receiving immune-modifying therapies or expected to receive immune-modifying therapies within the next 8 weeks. | 84.1% | 8.37 | 1.71 |
| IBD specialists should trust national and international regulatory bodies for appropriate review and authorisation of SARS-CoV-2 vaccinations. | 95.3% | 8.69 | 1.22 |
| The influence of IBD medications on the decision and timing for SARS-CoV-2 vaccination | |||
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving oral or topical 5-ASA medications. | 96.9% | 9.41 | 1.00 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving systemic corticosteroids. | 87.5% | 8.20 | 1.65 |
| Patients with IBD vaccinated with SARS-CoV-2 vaccine should be counselled that vaccine efficacy may be decreased when receiving systemic corticosteroids. | 92.5% | 8.53 | 1.99 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving thiopurine or methotrexate monotherapy. | 88.9% | 8.32 | 1.83 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving monotherapy with an anti-TNF agent. | 95.3% | 8.86 | 1.31 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving monotherapy with an anti-IL12/23 or anti-IL23 agent. | 90.3% | 8.69 | 1.53 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving monotherapy with an anti-integrin agent. | 93.8% | 9.08 | 1.34 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving a biologic in combination with a thiopurine or methotrexate. | 82.8% | 8.11 | 2.05 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving monotherapy with a JAK inhibitor. | 76.2% | 7.83 | 2.21 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is receiving monotherapy with an S1P receptor agonist. | 75.0% | 7.72 | 1.89 |
| SARS-CoV-2 vaccination should not be deferred because a patient with IBD is in a clinical trial for an IBD medication, as permitted per protocol. | 87.5% | 8.53 | 1.52 |
ASA, aminosalicylic acid; JAK, janus kinase; S1P, sphingosine-1-phosphate.; TNF, tumour necrosis factor.